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Introduction
Anaplastic lymphoma kinase (ALK) receptor is a tyrosine kinase encoded by the ALK gene. Gene fusion is the most frequent molecular alteration occurring in this gene across different tumor types including non-small cell lung cancer (NSCLC), leukemia, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and colorectal cancers (CRC) [1, 2] . ALK gene rearrangements lead to constitutive receptor dimerization and activation, resulting in uncontrolled tumor cell proliferation and activation of downstream MAPK and AKT pathways [3] .
Recent studies have shown that plasma circulating tumor DNA (ctDNA) can be used to effectively monitor response and emergence of resistance during the course of treatment with targeted agents [4] [5] [6] . While liquid biopsies are most commonly applied to plasma-derived ctDNA, recent analyses have focused on DNA isolated from other body fluids, such as cerebrospinal fluid, saliva and urine [7] [8] [9] . It is known that a portion of blood ctDNA is cleared by kidney barrier filtration and is excreted in urine in the form of small fragments (<100 bp) [10] . The applicability and clinical utility of liquid biopsies based on urine trans-renal DNA (tr-DNA) has not been extensively explored. Technical difficulties in detecting the highly fragmented and low abundant tumor-specific DNA in urine have limited progress in this field [10] .
We reasoned that PCR-based assays designed to detect genetic rearrangements such as the CAD-ALK translocation could be used to assess the validity of urine as a source of tumor-specific genetic information. A metastatic colorectal (mCRC) patient whose tumor displayed a CAD-ALK translocation showed a remarkable response during treatment with entrectinib, a potent and selective panTRK/ROS1/ALK inhibitor [11] . Here we exploited urine tr-DNA and matched blood ctDNA of this patient to monitor the CAD-ALK oncogenic rearrangement during ALK blockade.
Materials and methods

Patient's case report
The patient received treatment with entrectinib 400 mg/m 2 2 p.o. qd within the ALKA-372-001 phase I study (EudraCT Number: 2012-000148-88) for which she provided informed consent. Objective tumor response was measured by CT using the Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) [41] . Patient's urine and plasma samples were obtained through a study protocol approved by the Ethical Committee at Ospedale Niguarda, Milan, Italy.
Plasma and urine samples collection
At least 10 ml of whole blood were collected by blood draw using EDTA as anticoagulant. Plasma was separated within 5 h through two different centrifugation steps (the first at room temperature for 10 min at 1600 g and the second at 3000 g for the same time and temperature), obtaining up to 3 ml of plasma. Plasma was stored at À80 C until ctDNA extraction.
Urine samples, between 90 and 110 ml, were collected in the clinic into 120-ml cups, supplemented with preservative, and stored at or below À70 C.
ctDNA and tr-DNA isolation from plasma and urine ctDNA was extracted from plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen) according to the manufacturer's instructions. For urinary DNA extraction, urine was concentrated to 4 ml using Vivacell 100 concentrators (Sartorius Corp) and incubated with 700 ml of Q-sepharose Fast Flow quaternary ammonium resin (GE Healthcare). Tubes were spun to collect sepharose and bound DNA. The pellet was resuspended in a buffer containing guanidinium hydrochloride and isopropanol, and the eluted DNA was collected as a flow-through using polypropylene chromatography columns (Bio-Rad). The DNA was further purified using Qia-Quick columns (Qiagen). tr-DNA fragment size distribution was assessed using the 2100 Bioanalyzer High-Sensitivity DNA assay kit (Agilent Technologies) according to the manufacturer's instructions.
Droplet digital PCR analysis
Isolated circulating free DNA was amplified using ddPCR TM Supermix for Probes (Bio-Rad) with ALK p.F1174C, p.F1174L (C>G and T>C), p.G1128A, p.F1245V, and TP53 p.R248W assays (custom designed probes). ddPCR was then carried out according to the manufacturer's protocol and the results were reported as percentage or fractional abundance of mutant DNA alleles to total (mutant plus WT) DNA alleles.
A total of 8-10 ml of DNA template was added to 10 ml of ddPCR Supermix for Probes (Bio-Rad) and 2 ml of the primer and probe mixture. Droplets were generated using Auto-DG where the reaction mix was added together with Droplet Generation Oil for Probes (Bio-Rad). Droplets were then transferred to a 96-well plate (Eppendorf) and then thermal cycled with the following conditions: 5 min at 95 C, 40 cycles of 94 C for 30s, 55 C for 1 min followed by 98 C for 10 min (Ramp Rate 2 C/s). Droplets were analyzed with the QX200 Droplet Reader (BioRad) for fluorescent measurement of FAM and HEX probes. Gating was carried out based on positive and negative controls, and mutant populations were identified. The ddPCR data were analyzed with QuantaSoft analysis software (Bio-Rad) to obtain fractional abundance of the mutated alleles in the WT or normal background. The quantification of the target molecule was presented as number of total copies (mutant plus WT) per sample in each reaction. The number of positive and negative droplets is used to calculate the concentration of the target and reference DNA sequences and their Poisson-based 95% confidence intervals, as previously shown [18] . ddPCR analysis of normal control DNA (from cell lines) and no DNA template controls were always included. Samples with too low positive events were repeated at least twice in independent experiments to validate the obtained results.
End-point PCR analysis
End-point PCR was carried out as follows: ctDNA and tr-DNA with 0.05 U of platinum Taq DNA polymerase (Invitrogen), 1Â platinum buffer (Invitrogen), 1 mM dNTPs (Invitrogen), 1.5 mM MgCl2 (Invitrogen), 1 mM of each primer were amplified using the following cycling conditions: TOPO TA cloning and Sanger sequencing CAD-ALK specific amplicon obtained by end-point PCR carried out on gDNA obtained from the PDX (positive control), plasma ctDNA and urine tr-DNA were cloned in TOP10 competent cells using the TOPO V R
TA Cloning
V R Kit for Sequencing (Life Technologies) according to the manufacturer's protocol. Samples were then subjected to automated sequencing by ABI PRISM 3730 (Applied Biosystems) with M13 reverse primer.
PNA assays
PNA-mediated clamped PCR was carried out as follows: tr-DNA with 0.05 U of platinum Taq DNA polymerase (Invitrogen), 1X platinum buffer (Invitrogen), 1 mM dNTPs (Invitrogen), 1.5 mM MgCl2 (Invitrogen), 1 mM of each primer, and 35 nM of custom designed TP53 codon 248 PNA (NH2-TGAACCGGAGGCCCATCC-CONH2) was amplified with the following conditions: 5 min at 95 C, 40 cycles of 94 C for 30 s, 85 C for 30 s, 55 C for 1 min followed by 98 C for 10 min (Ramp Rate 2 C/s). Bands were quantified as per End-Point PCR procedure above.
IRCC-FUSION and IRCC-TARGET next generation sequencing panels
IRCC-FUSION panel was designed selecting the most recurrent seven kinase fusions in cancer. For all of them the most frequent rearrangement partners were identified. Capture probes were designed exploiting the tool available online (https://designstudio.illumina.com), covering the exon and intron of the upstream 5 0 and the downstream 3 0 partner (supplementary Table S1A , available at Annals of Oncology online).
The panel also covers: hot-spot mutations previously associated with resistance to EGFR blockade in CRC (KRAS, NRAS, BRAF, PIK3CA, MAP2K1, EGFR); promoter of the epidermal growth factor receptor (EGFR) ligands; all coding exons of four genes known to be involved in CRC tumorigenesis (PTEN, TP53, APC, CTNNB1) (supplementary Table S1B , available at Annals of Oncology online).
Libraries were prepared with Nextera Rapid Capture Custom Enrichment Kit (Illumina, Inc., San Diego, CA), according to the manufacturer's protocol. Libraries preparation was carried out using up to 150 ng of plasma ctDNA with NEBNext V R Ultra TM DNA Library Prep Kit for Illumina V R (New England BioLabs, Inc., Ipswich, MA), with optimized protocol. ctDNA was then used as template for indexing PCR which allows the introduction of unique sample barcodes. DNA fragments' size distribution was assessed using the 2100 Bioanalyzer with the High Sensitivity DNA assay kit (Agilent Technologies, Santa Clara, CA). Equal amount of DNA libraries were pooled and subjected to targeted panel hybridization capture. Libraries were then sequenced on the Illumina MiSeq sequencer (Illumina, Inc.). Full description of IRCC-TARGET panel can be found in [5] .
Bioinformatic analysis
To detect the CAD-ALK rearrangement, a mix of BWA [42] and BLAT [43] was used. Reads were first aligned with BWA to the hg19 human reference genome. Afterwards, reads that were not perfectly aligned by BWA, potentially harboring translocations, were further processed using BLAT (tileSize ¼ 11, stepSize ¼ 5). The resulting PSL alignment was postprocessed with a custom built script to detect alignments supporting translocations events. Gene fusion calling was carried out according to the following criteria: each fusion partner must have at least 25 nucleotides mapped to the respective part of the read; the fusion partners must map to two different genes; each fusion breakpoint must be supported by at least 10 reads.
To detect somatic variation, FastQ files generated by Illumina MiSeq were mapped to the human reference (assembly hg19) using BWA-mem algorithm [42] . Sequences were then processed to remove all bases in the read with a Phred quality score less than 20. PCR duplicates were removed using the SAMtools package [44] . Somatic variations were called according to previously published methods [5] . A mutational analysis with IRCC-TARGET panel was carried out comparing the pre-and post-treatment samples; with IRCC-FUSION panel, the human genome (hg19) was used as reference to call somatic variations. Mutations were annotated printing out gene information, number of normal and mutated reads, allelic frequencies, variation effect and the association of each hit with the corresponding number of occurrences in the COSMIC database [45] .
Results
Acquired resistance to ALK inhibition in a CRC patient
A molecular screen identified a 53-year-old mCRC patient with brain, thoracic lymph nodes and liver metastases carrying a CAD-ALK gene fusion [11] . After several rounds of standard treatments including surgery on the primary tumor (right hemicolectomy), external beam radiation therapy to the central nervous system (CNS) metastases (brain and cerebellum) and thoracic lymph nodes, and two lines of chemotherapy (both with oxaliplatin, 5-fluorouracil/leucovorin, and bevacizumab), administered before and after the radiation therapy, the patient displayed disease progression in the liver metastases.
The patient's tumor harbored a rearrangement involving CAD exon 35 to ALK exon 20. We and others have previously reported that CRC cell models harboring ALK translocations are sensitive to ALK pharmacological inhibition [1, 12] .
Based on this evidence, the patient was enrolled in the phase I clinical trial (EudraCT Number 2012-000148-88) of the panTRK/ROS1/ALK kinase inhibitor entrectinib, a first-in-class drug currently undergoing clinical testing [13, 14] .
The patient received entrectinib on a 400 mg/m 2 p.o qd (by mouth daily) dosing schedule. Computed tomography (CT) scan evaluations were planned as per protocol every 8 weeks. In case of PR/CR, confirmation of response by another CT scan was mandatory after 4 weeks. At baseline in March 2015, a CT scan revealed stable and asymptomatic CNS disease (brain and cerebellum), and right and left liver lobe involvement. The treatment induced remarkable tumor shrinkage and was well tolerated, leading to a rapid partial response with a decrease in the sum of the target lesions by 38%, confirmed by a subsequent CT scan in July 2015 ( Figure 1A ). Brain and cerebellum metastases remained stable over the duration of the treatment. After 18 weeks of clinical response, drug resistance occurred, as evaluated by a CT scan in late August 2015, and the patient died in September 2015 due to progression of liver disease and hepatic failure.
Detection of CAD-ALK gene fusion in plasma ctDNA
To identify the CAD-ALK fusion genomic breakpoint, we analyzed plasma ctDNA through liquid biopsy [15] , an approach we previously optimized to detect and monitor drug resistance in patients treated with targeted agents [4, 16] .
ctDNA isolated from a plasma sample collected before treatment initiation (baseline) was subjected to molecular profiling using a next generation sequencing (NGS) panel (IRCC-FUSION panel) we purposely designed to interrogate 52 common cancer gene rearrangements (supplementary Table S1A , available at Annals of Oncology online) and 14 frequently mutated genes in cancer patients (supplementary Table S1B , available at Annals of Oncology online). Profiling of the pre-treatment specimen unveiled a TP53 p.R248W mutation and detected the CAD-ALK gene fusion (supplementary Table S2A , available at Annals of Oncology online), that was also present in the tumor tissue of the same individual [11] .
The ALK rearrangement is present in urine tr-DNA and mirrors patient's response Urine (90-110 ml of first morning void) and blood samples were longitudinally collected during treatment with the ALK inhibitor. Urine tr-DNA was isolated as described in the methods section and fragments' size distribution was evaluated using a 2100 Bioanalyzer (supplementary Figure S1 , available at Annals of Oncology online). The amount of tr-DNA extracted from the baseline urine sample (March 2015) was not sufficient to perform the analyses and was excluded (supplementary Figure S1A , available at Annals of Oncology online).
Urine tr-DNA differs from plasma ctDNA in that there is a large amount of contaminating normal DNA, consisting of high-molecular weight fragments, shed by cells of the urinary tract into urine. A standard droplet digital PCR (ddPCR) [17] approach failed to detect the rearrangement in tr-DNA. We reasoned that highly sensitive assays would be needed to detect the CAD-ALK rearrangement and the TP53 mutation in tr-DNA. We designed several end-point PCR assays to detect the CAD-ALK gene fusion. We found that a 51-bp assay was optimally suited to detect the translocation in tr-DNA ( Figure 1B ; supplementary Figure S2A , available at Annals of Oncology online).
Using the amplicon-based assay, the presence of the gene fusion was detectable in all urine and plasma time-points analyzed ( Figure 1B ; supplementary Figure S2 , available at Annals of Oncology online). The tr-DNA from an unrelated CRC patient served as a negative control. CAD-ALK levels increased in August 2015 when the patient showed clinical progression ( Figure 1B) . Of note, the CAD-ALK gene fusion was apparent in urine tr-DNA before radiological confirmation of progressive disease ( Figure 1B ; supplementary Figure S2A , available at Annals of Oncology online). To validate the specificity of the assay we carried out TOPO TA cloning of the PCR products followed by Sanger sequencing. The results confirmed the presence of the genomic rearrangement (supplementary Figure S3 , available at Annals of Oncology online). To detect the TP53 p.R248W variant, as an alternative marker of tumor burden and response to treatment in urine tr-DNA, peptide nucleic acid (PNA) probes were designed to specifically suppress amplification of wild-type (WT) fragments. TP53 mutated alleles were detected in all time-points (supplementary Figure S4 , available at Annals of Oncology online).
Emergence of secondary ALK mutations in plasma ctDNA during entrectinib treatment
To uncover molecular alterations associated with emergence of secondary resistance to entrectinib treatment, plasma ctDNA obtained at clinical relapse was investigated with the NGS-based IRCC-TARGET panel we previously described [4] . ctDNA profiling at progression to entrectinib confirmed the presence of the TP53 p.R248W mutation already detected in the baseline plasma sample by the IRCC-FUSION panel NGS analysis (data not shown). Additionally, the analysis revealed five ALK point mutations in exons 21, 23, and 24 (p.F1174C, p.F1174L C>G and T>C, p.G1128A and p.F1245V) in the kinase domain of the protein, which were not detected in ctDNA obtained before entrectinib treatment (supplementary Table S2B , available at Annals of Oncology online).
To longitudinally monitor mutant ALK alleles in plasma samples collected over the course of treatment, ddPCR assays were designed for individual mutations. To monitor overall disease, the TP53 p.R248W founder mutation, as identified by NGS (supplementary Table S2A , available at Annals of Oncology online), was also followed by ddPCR analysis in plasma ctDNA (Figure 2 ). Longitudinal ddPCR analysis of plasma ctDNA revealed that ALK mutations were initially absent (or present at very low levels) and emerged as early as 8 weeks upon initiation of treatment with entrectinib ( Figure 2 ; supplementary Table S3 , available at Annals of Oncology online). ALK mutant allele fractions continued to increase in plasma ctDNA until clinical progression was radiologically confirmed (20 weeks after initiation of treatment).
Discussion
Mechanisms of resistance to targeted therapies are usually investigated by molecular profiling of a tissue biopsy obtained at progression. However, tumor heterogeneity and biases associated with tissue sampling limit the effectiveness of this strategy. In addition, tissue biopsies are not always feasible and are associated with risks due to the invasiveness of the procedure.
To address these issues we and others exploited plasma ctDNA to genotype solid tumors non-invasively and monitor clonal evolution during treatment with targeted agents [4, 6, [19] [20] [21] [22] . However, blood draws are not exactly non-invasive and phlebotomy requires the involvement of a health professional. Furthermore, the blood volume is limited, and its collection can be impaired by health conditions and other reasons; this affects the frequency of collection, limiting patient's monitoring in real time.
In principle, these limitations can be overcome using circulating tr-DNA [23, 24] . Urine can be collected at home and there are no quantitative or timing limitations to sample collection. This may be particularly valuable in some clinical settings, for example monitoring minimal residual disease (MRD) after surgery with curative intent. In this situation, one can envision the patient collecting urine at home over several days (weeks) followed by centralized analyses of trans-renal DNA aimed at identification of cancerspecific alterations to determine MRD. We also note that recent evidence indicates that urine tr-DNA analysis can reach remarkable sensitivity when using appropriate sample volumes [7, 25] .
Only a limited number of studies have exploited DNA extracted from urine for the molecular characterization of cancer patients [7, [26] [27] [28] [29] . Concordance among somatic mutations detected in matched tumor tissue, plasma, and urine has been reported [7, 30] . These studies include KRAS mutations in CRC, BRAF mutations in histiocytic disorders and EGFR mutations in NSCLC [7, 27] . Several reasons have limited the use of tr-DNA as a source of tumor-specific genomic information. For example, it is currently unclear what fraction of cancer patients carry tumorderived DNA fragments in urine. Another limitation to the use of tr-DNA is that tumor DNA represents a very low fraction of the total tr-DNA, and therefore detection assays must be highly sensitive. We reasoned that oncogenic rearrangements (gene fusions) would be uniquely suited for urine-based assays since PCR reactions spanning somatically rearranged loci are not influenced by the presence of WT DNA that is found in large amounts in urine.
To provide proof of concept that this approach is feasible, we studied urine tr-DNA and matched plasma ctDNA of a patient with a CAD-ALK rearranged mCRC who received the ALK kinase inhibitor, entrectinib. Our findings suggest that detection of gene fusions in urine tr-DNA is feasible and that its dynamics during treatment with a targeted agent parallel changes observed in plasma ctDNA.
Sequencing plasma ctDNA further revealed that during entrectinib treatment several ALK mutations (p.F1174C, p.F1174L, p.F1245V, and p.G1128A) emerged. These variants were reported in both familial and sporadic neuroblastoma [31] [32] [33] [34] and were also functionally linked to secondary resistance to other ALK inhibitors in NSCLC, as well as in neuroblastoma [32, [35] [36] [37] . p.F1174 is one of the most common hotspot mutations in exon 23, which is located at the end of the kinase domain C-helix [3] , with the occurrence of p.F1174L and the p.F1174C alterations being the most and least frequent, respectively (37% and 4% among ALK mutant neuroblastomas) [31] . The p.G1128A mutation (exon 21) was found in neuroblastoma, and is located in the glycine-rich P loop, generating a gain of function kinase [3, 38] . Although the mechanism of activation is not clear, this mutation presumably alters interaction of the kinase domain with ATP increasing phosphate transfer. The ALK p.F1245V mutation in exon 24, previously observed in sporadic neuroblastoma [3] , is located in the tyrosine kinase domain, and corresponds to the L833 residue of EGFR, a mutation which is associated with gefitinib resistance in lung cancer [32] . Mutations occurring at codons 1174 and 1245 have a strong effect on ALK receptor auto-phosphorylation due to the destabilization of ALK's auto inhibitory interaction and promotion of tyrosine kinase domain activation [38] . Of note, the p.F1174L mutation, that we detected at resistance to entrectinib, is sensitive to second-generation ALK inhibitors such as alectinib and TAE684 [32, 39] . Similarly, ASP3026 displays activity against the activating ALK mutants p.F1174L and p.R1275Q and against the crizotinibresistant gatekeeper mutation L1196M [40] . Our data suggest that additional lines of therapy based on already available ALK inhibitors could be administered concomitantly to prevent or overcome the emergence of resistance.
In summary, we find that urine-based genetic testing allows the tracing of tumor-specific oncogenic rearrangements. This strategy could be effectively applied to non-invasively monitor tumor evolution during therapy. The same approach could also be employed to monitor MRD after surgery with curative intent in patients whose tumors carry gene fusions. The strategy does not require patient hospitalization since urine DNA can be self-collected, is stable over time and can be shipped to central labs for testing [23] .
Here, we provide proof of concept data that tr-DNA can be effective in monitoring tumor evolution. The approach should now be validated in large number of patients.
While this study assessed a limited number of genetic variants in tr-DNA, in the future NGS approaches will likely provide a more comprehensive landscape of tr-DNA. While the analysis of trans-renal tumor DNA are presently complex and limited by sensitivity, advances on DNA sequencing technologies will likely overcome current limitations.
